Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8039627 | NEUROCRINE | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto |
Apr, 2031
(6 years from now) | |
US10844058 | NEUROCRINE | Valbenazine salts and polymorphs thereof |
Oct, 2036
(12 years from now) | |
US10851104 | NEUROCRINE | Valbenazine salts and polymorphs thereof |
Oct, 2036
(12 years from now) | |
US10851103 | NEUROCRINE | Valbenazine salts and polymorphs thereof |
Oct, 2036
(12 years from now) | |
US10065952 | NEUROCRINE | Valbenazine salts and polymorphs thereof |
Oct, 2036
(12 years from now) | |
US10906903 | NEUROCRINE | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
Dec, 2036
(12 years from now) | |
US10906902 | NEUROCRINE | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
Dec, 2036
(12 years from now) | |
US10919892 | NEUROCRINE | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
Dec, 2036
(12 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8357697 | NEUROCRINE | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto |
Nov, 2027
(3 years from now) | |
US11040029 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(13 years from now) | |
US10912771 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(13 years from now) | |
US10993941 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(13 years from now) | |
US11439629 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(13 years from now) | |
US10952997 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(13 years from now) | |
US10874648 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(13 years from now) | |
US10857137 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(13 years from now) | |
US10857148 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(13 years from now) | |
US11026939 | NEUROCRINE | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
Sep, 2038
(14 years from now) | |
US11311532 | NEUROCRINE | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
Sep, 2038
(14 years from now) | |
US11654142 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Nov, 2038
(14 years from now) | |
US11026931 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Aug, 2039
(15 years from now) | |
US10940141 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Aug, 2040
(16 years from now) |
Ingrezza is owned by Neurocrine.
Ingrezza contains Valbenazine Tosylate.
Ingrezza has a total of 22 drug patents out of which 0 drug patents have expired.
Ingrezza was authorised for market use on 11 April, 2017.
Ingrezza is available in capsule;oral dosage forms.
Ingrezza can be used as a method of treating huntington's chorea, method of administering valbenazine while avoiding concomitant use of a strong cyp3a4 inducer, treatment of tardive dyskinesia.
Drug patent challenges can be filed against Ingrezza from 11 April, 2021.
The generics of Ingrezza are possible to be released after 10 August, 2040.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-440) | Aug 18, 2030 |
New Indication(I-925) | Aug 18, 2026 |
New Chemical Entity Exclusivity(NCE) | Apr 11, 2022 |
Drugs and Companies using VALBENAZINE TOSYLATE ingredient
NCE-1 date: 11 April, 2021
Market Authorisation Date: 11 April, 2017
Treatment: A method of treating huntington's chorea; Treatment of tardive dyskinesia; Method of administering valbenazine while avoiding concomitant use of a strong cyp3a4 inducer
Dosage: CAPSULE;ORAL